ISRCTN ISRCTN72347535
DOI https://doi.org/10.1186/ISRCTN72347535
Integrated Research Application System (IRAS) 1014425
Sponsor ALLInBio, Inc.
Funder ALLInBio, Inc.
Submission date
10/11/2026
Registration date
18/11/2026
Last edited
18/11/2026
Recruitment status
Not yet recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

ALLInBio, Inc.
Public, Scientific

ALLInBio, Inc. 3160 Porter Driver, Suite 200
Palo Alto, CA
94304
United States of America

Phone +1 415-725-6030
Email clinicaltrials@allinbio.com
Dr Denisa Wilkes
Principal investigator

Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, Park Royal
London
NW10 7EW
United Kingdom

ORCiD logoORCID ID 0009-0007-3133-5152
Phone +44 (0)20 8961 4130
Email rec@hmrlondon.com

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingBlinded (masking used)
ControlPlacebo
AssignmentThe sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
PurposePhase I trial in healthy participants
Scientific titleHMR code: 26-501
Full scientific title to be added on or before the deferral expiry date
Study objectives The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)

Submitted 21/09/2026, London – Brent Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8129; brent.rec@hra.nhs.uk), ref: 26/LO/0478

Health condition(s) or problem(s) studiedThe sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
InterventionThe sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Primary outcome measure(s)
  1. [Outcome] measured using [measure] at [timepoints]. The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)

The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

Completion date02/06/2028

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit80 Years
SexAll
Target sample size at registration148
Key inclusion criteriaThe sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteriaThe sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment30/11/2026
Date of final enrolment16/08/2027

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Hammersmith Medicines Research (HMR)
Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, Park Royal
London
NW10 7EW
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

17/11/2026: Trial's existence confirmed by MHRA.